Panacea Life Sciences Holdings Q3 FY23: revenue $348K, down 5%; diluted EPS −$0.13

Key figures from this report

These are the numbers Panacea Life Sciences Holdings reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$348K−5% from $366K in Q3 FY2210-Q income statement, on EDGAR
2. Net income−$2.2MAgainst −$2.7M in Q3 FY2210-Q income statement, on EDGAR
3. Diluted EPS−$0.13Against −$0.18 in Q3 FY2210-Q income statement, on EDGAR
4. Cash and cash equivalents$1K−96% from $37K in Q3 FY22Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$729KAgainst −$711K in Q3 FY2210-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables